Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CJM112 in hidradenitis suppurativa completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• CJM112

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Status: COMPLETED | Results posted: 2019-05-23